KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Taxes (2016 - 2021)

Biocryst Pharmaceuticals filings provide 7 years of Current Taxes readings, the most recent being $2.6 million for Q4 2021.

  • On a quarterly basis, Current Taxes rose 3177.5% to $2.6 million in Q4 2021 year-over-year; TTM through Dec 2021 was $2.6 million, a 3177.5% increase, with the full-year FY2021 number at $2.6 million, up 3177.5% from a year prior.
  • Current Taxes hit $2.6 million in Q4 2021 for Biocryst Pharmaceuticals, up from $80000.0 in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $2.6 million in Q4 2021 to a low of $51000.0 in Q4 2018.
  • Median Current Taxes over the past 5 years was $80000.0 (2020), compared with a mean of $593600.0.
  • Biggest five-year swings in Current Taxes: crashed 65.54% in 2018 and later skyrocketed 3177.5% in 2021.
  • Biocryst Pharmaceuticals' Current Taxes stood at $148000.0 in 2017, then tumbled by 65.54% to $51000.0 in 2018, then surged by 31.37% to $67000.0 in 2019, then increased by 19.4% to $80000.0 in 2020, then skyrocketed by 3177.5% to $2.6 million in 2021.
  • The last three reported values for Current Taxes were $2.6 million (Q4 2021), $80000.0 (Q4 2020), and $67000.0 (Q4 2019) per Business Quant data.